Neurological Sciences

, Volume 36, Issue 6, pp 1075–1081 | Cite as

Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice

  • Ugo Paolo Guerra
  • Flavio Mariano Nobili
  • Alessandro PadovaniEmail author
  • Daniela Perani
  • Alberto Pupi
  • Sandro Sorbi
  • Marco Trabucchi
News and Views


Positron emission tomography (PET) of brain amyloid is a technology that has been approved by Food and Drug Administration and European Medical Agency, but its clinical utility in medical practice requires careful definition. To provide guidance to italian dementia care practitioners, patients, and caregivers, a group of experts from “Associazione Italiana di Medicina Nucleare” (AIMN), “Associazione Italiana di Psicogeriatria” (AIP) and “Società Italiana per lo Studio delle Demenze” (SINDEM) convened the Italian Interdisciplinary Working Group on Amyloid Imaging. The Working Group considered a range of clinical scenarios in which amyloid PET should be recommended. Peer-reviewed, published literature was searched to ascertain available evidence relevant to these recommendations. Although empirical evidence of impact on clinical outcomes is not yet available, a set of specific recommended use criteria were agreed to define the types of patients and clinical circumstances in which amyloid PET could be used. Both correct and incorrect uses were considered and formulated. Because both dementia care and amyloid-PET technology are in active development, these recommendations will require periodic reassessment.


Alzheimer disease Neuroimaging Amyloid imaging Positron emission tomography Clinical practice 


Conflict of interest

Alessandro Padovani has received honoraria for speaking at Symposia from General Electrics-Health, Lundbeck, and Novartis; Flavio Mariano Nobili has received honoraria for speaking at Symposia from Eli Lilly & Co and Piramall; Ugo Paolo Guerra, Daniela Perani, Sandro Sorbi, Alberto Pupi and Marco Trabucchi declare that they have no conflict of interest.


  1. 1.
    Musicco M, Padovani A, Sorbi S, Scarpini E, Caffarra P, Cappa S et al (2012) Position paper of the Italian Society for the study of Dementias (SINDEM) on the proposal of a new lexicon on Alzheimer disease. Neurol Sci 33(1):201–208PubMedCrossRefGoogle Scholar
  2. 2.
    Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P et al (2010) Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9:1118–1127PubMedCrossRefGoogle Scholar
  3. 3.
    Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH; Alzheimer’s Association; Society of Nuclear Medicine and Molecular Imaging; Amyloid Imaging Taskforce (2013) Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement 9(1):e-1–e-16Google Scholar
  4. 4.
    Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Hedrick S, Pappas V, Carrillo MC, Hartley DM (2013) Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med 54(7):1011–1013PubMedCrossRefGoogle Scholar
  5. 5.
    Vandenberghe R, Adamczuk K, Dupont P, Laere KV, Chételat G (2013) Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer’s disease. Neuroimage Clin 6(2):497–511CrossRefGoogle Scholar
  6. 6.
    Rowe C, Villemagne VL (2013) Amyloid imaging with PET in early Alzheimer disease diagnosis. Med Clin N Am 97:377–398PubMedCrossRefGoogle Scholar
  7. 7.
    Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, de Leon MJ, Kaye J, Reiman EM, Scheltens P, Barkhof F, Black SE, Brooks DJ, Carrillo MC, Fox NC, Herholz K, Nordberg A, Jack CR Jr, Jagust WJ, Johnson KA, Rowe CC, Sperling RA, Thies W, Wahlund LO, Weiner MW, Pasqualetti P, Decarli C, ISTAART’s NeuroImaging Professional Interest Area (2013) Imaging markers for Alzheimer disease: which vs how. Neurology 81(5):487–500PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Perani D (2014) FDG-PET and amyloid-PET imaging: the diverging paths. Curr Opin Neurol 27(4):405–413PubMedCrossRefGoogle Scholar
  9. 9.
    Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, Feng J (2014) (11)C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 23:7Google Scholar
  10. 10.
    Booij J, Arbizu J, Darcourt J, Hesse S, Nobili F, Payoux P, Pappatà S, Tatsch K, Walker Z, Pagani M (2013) Appropriate use criteria for amyloid-PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging 40(7):1122–1125PubMedCrossRefGoogle Scholar
  11. 11.
    Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13(6):614–629PubMedCrossRefGoogle Scholar
  12. 12.
    Jack CR Jr, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, Lowe VJ, Senjem ML, Gunter JL, Preboske GM, Pankratz VS, Vemuri P, Petersen RC (2014) Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. Lancet Neurol 13(10):997–1005PubMedCrossRefGoogle Scholar
  13. 13.
    Ruiqing Ni Gillberg PG, Bergfors A, Marutle A, Nordberg A (2013) Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain 136(7):2217–2227CrossRefGoogle Scholar
  14. 14.
    Vallabhajosula S (2011) Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid. Semin Nucl Med 41(4):283–299PubMedCrossRefGoogle Scholar
  15. 15.
    Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, Pontecorvo M, Baker SL, Jagust WJ, Alzheimer’s Disease Neuroimaging Initiative (2014) Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 41(7):1398–1407PubMedCrossRefGoogle Scholar
  16. 16.
    Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):270–279PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J (1992) Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55(10):967–972PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P, European Task Force on Age-Related White Matter Changes (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32(6):1318–1322PubMedCrossRefGoogle Scholar
  20. 20.
    Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ, Alzheimer’s Disease Neuroimaging Initiative (2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 72(4):578–586PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12):1863–1872PubMedCrossRefGoogle Scholar
  22. 22.
    Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM et al (2012) Florbetapir PET analysis of β-amyloid deposition in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred: a cross-sectional study. Lancet Neurol 11:1057–1065PubMedCrossRefGoogle Scholar
  23. 23.
    Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P et al (2011) Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 69:181–192PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Viswanathan A, Greenberg SM (2011) Cerebral amyloid angiopathy in the elderly. Ann Neurol 70(6):871–880PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Ly JV, Donnan GA, Villemagne VL, Zavala JA, Ma H, O’Keefe G, Gong SJ, Gunawan RM, Saunder T, Ackerman U, Tochon-Danguy H, Churilov L, Phan TG, Rowe CC (2010) 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 74(6):487–493PubMedCrossRefGoogle Scholar
  26. 26.
    Yates PA, Sirisriro R, Villemagne VL, Farquharson S, Masters CL, Rowe CC, AIBL Research Group (2011) Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease. Neurology 77(1):48–54PubMedCrossRefGoogle Scholar
  27. 27.
    Dierksen GA, Skehan ME, Khan MA, Jeng J, Nandigam RN, Becker JA, Kumar A, Neal KL, Betensky RA, Frosch MP, Rosand J, Johnson KA, Viswanathan A, Salat DH, Greenberg SM (2010) Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol 68(4):545–548PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Gurol ME, Dierksen G, Betensky R, Gidicsin C, Halpin A, Becker A, Carmasin J, Ayres A, Schwab K, Viswanathan A, Salat D, Rosand J, Johnson KA, Greenberg SM (2012) Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology 79(4):320–326PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Baron JC, Farid K, Dolan E, Turc G, Marrapu ST, O’Brien E, Aigbirhio FI, Fryer TD, Menon DK, Warburton EA, Hong YT (2014) Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage. J Cereb Blood Flow Metab 34(5):753–758PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R, Robins P, Tochon-Danguy H, O’Keefe G, Pike KE, Yates P, Szoeke C, Salvado O, Macaulay SL, O’Meara T, Head R, Cobiac L, Savage G, Martins R, Masters CL, Ames D, Villemagne VL (2013) Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 74(6):905–913PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2015

Authors and Affiliations

  • Ugo Paolo Guerra
    • 1
  • Flavio Mariano Nobili
    • 2
  • Alessandro Padovani
    • 3
    Email author
  • Daniela Perani
    • 4
  • Alberto Pupi
    • 5
  • Sandro Sorbi
    • 6
  • Marco Trabucchi
    • 7
    • 8
  1. 1.Nuclear Medicine, Fondazione Poliambulanza, Istituto OspedalieroBresciaItaly
  2. 2.Clinical Neurology, Department of Neuroscience (DINOGMI)University of GenoaGenoaItaly
  3. 3.Neurology Unit, Department Clinical and Experimental SciencesUniversity of BresciaBresciaItaly
  4. 4.Nuclear Medicine Unit San Raffaele Hospital and Division of Neuroscience, San Raffaele Scientific InstituteVita-Salute San Raffaele UniversityMilanItaly
  5. 5.Nuclear Medicine, Dipartimento di Scienze Biomediche, Sperimentali e Cliniche “Mario Serio”University of FlorenceFlorenceItaly
  6. 6.NEUROFARBA (Department of Neuroscience, Psychology, Drug Research and Child Health)University of FlorenceFlorenceItaly
  7. 7.University of Tor VergataRomeItaly
  8. 8.Geriatric Research GroupBresciaItaly

Personalised recommendations